Autoantibodies against type I IFNs in patients with life-threatening COVID-19

Mostra el registre complet Registre parcial de l'ítem

• dc.contributor.author Bastard, Paul
• dc.contributor.author Gut, Marta
• dc.contributor.author Casanova, Jean-Laurent
• dc.date.accessioned 2022-07-08T06:39:56Z
• dc.date.available 2022-07-08T06:39:56Z
• dc.date.issued 2020
• dc.description.abstract Interindividual clinical variability in the course of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection is vast. We report that at least 101 of 987 patients with life-threatening coronavirus disease 2019 (COVID-19) pneumonia had neutralizing immunoglobulin G (IgG) autoantibodies (auto-Abs) against interferon-ω (IFN-ω) (13 patients), against the 13 types of IFN-α (36), or against both (52) at the onset of critical disease; a few also had auto-Abs against the other three type I IFNs. The auto-Abs neutralize the ability of the corresponding type I IFNs to block SARS-CoV-2 infection in vitro. These auto-Abs were not found in 663 individuals with asymptomatic or mild SARS-CoV-2 infection and were present in only 4 of 1227 healthy individuals. Patients with auto-Abs were aged 25 to 87 years and 95 of the 101 were men. A B cell autoimmune phenocopy of inborn errors of type I IFN immunity accounts for life-threatening COVID-19 pneumonia in at least 2.6% of women and 12.5% of men.
• dc.format.mimetype application/pdf
• dc.identifier.citation Bastard P, Rosen LB, Zhang Q, Michailidis E, Hoffmann HH, Zhang Y, et al. Autoantibodies against type I IFNs in patients with life-threatening COVID-19. Science. 2020 Oct 23; 370(6515): eabd4585. DOI: 10.1126/science.abd4585
• dc.identifier.doi http://dx.doi.org/10.1126/science.abd4585
• dc.identifier.issn 0036-8075
• dc.identifier.uri http://hdl.handle.net/10230/53698
• dc.language.iso eng
• dc.publisher American Association for the Advancement of Science (AAAS)
• dc.rights This is an open-access article distributed under the terms of the Creative Commons Attribution license http://creativecommons.org/licenses/by/4.0/, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
• dc.rights.accessRights info:eu-repo/semantics/openAccess
• dc.rights.uri http://creativecommons.org/licenses/by/4.0/
• dc.subject.other Antibodies, Neutralizing
• dc.subject.other COVID-19
• dc.subject.other Asymptomatic Infections
• dc.subject.other Betacoronavirus
• dc.subject.other Coronavirus Infections
• dc.subject.other Interferon Type I
• dc.title Autoantibodies against type I IFNs in patients with life-threatening COVID-19
• dc.type info:eu-repo/semantics/article
• dc.type.version info:eu-repo/semantics/publishedVersion